Thursday’s Top Biotech and Medical Stocks

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

From BioHealth Investor

by Mark S. Senak

As the lame duck Senate gets ready to waddle off to their place in history, they have moved to pass S. 3546 – a bill that would require the makers of dietary supplements to report serious adverse events.

Interestingly, this development coincides with a lawsuit launched earlier this week against a maker of Fen-Phen.

The bill which passed yesterday, defines a serious adverse event as “reports of a death, a life-threatening experience, hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect.”

It remains to be seen whether or not this is the beginning of a broader reform movement aimed at the supplement industry, or perhaps will satisfy those hungry for reform. Likewise, if the bill becomes law, it represents another mandate on the FDA, to whom the SAEs would be reported that adds to the scope and therefore the expense of running the agency, increasingly reliant on PDUFA fees to do so.

While the bill is not yet law yet, one thing the supplement industry might consider is to get ahead of the law and begin reporting SAEs now, rather than being forced to later. This could be done either through an association, consumer group or a large manufacturer could take the first step. In any event, since reform is on the way, it might be a good idea to get as much ahead of the curve as possible.

_

Add to Yahoo MyWeb2Digg This!Add to del.icio.usAdvertise in The Business of Biotech

Thursday’s Top Biotech and Medical Stocks

Biotechnology

VANDA PHARMACEUTICAL [VNDA] +68.71%
TITAN PHARMA INC [TTP] +54.01%
HALOZYME THERAPEUTIC [HTI] +25.93%
TARGETED GENETICS CP [TGEN] +12.98%
ALFACELL CORP [ACEL] +10.49%

Diagnostic Substances

IMMUNOMEDICS INC [IMMU] +9.96%
HEALTHCARE TECH LTD [HCTL] +9.20%
EPIX PHARMACEUTICALS [EPIX] +8.07%
THRESHOLD PHARMACEUT [THLD] +3.48%
SYNOVA HEALTHCARE GR [SNVH.OB] +2.56%

Drug Delivery

SYMBOLLON PHARM CL A [SYMBA.OB] +9.09%
BIOVAIL CORP [BVF] +7.72%
INSITE VISION INC [ISV] +2.29%
PETMED EXPRESS INC [PETS] +2.16%
FLAMEL TECH SA ADR [FLML] +1.95%

Drug Manufacturers

PLANET TECHS INC [PLNT.OB] +127.27%
ARQULE INC [ARQL] +10.79%
TAPESTRY PHARMA INC [TPPH] +7.41%
PROVECTUS PHARMA [PVCT.OB] +6.25%
GERON CORP [GERN] +4.96%

Medical Appliances & Equipment

SYNERGETICS USA INC [SURG] +6.60%
MICROTEK MED HLDGS [MTMD] +5.57%
ASPECT MEDICAL SYS [ASPM] +4.60%
HEALTHTRONICS INC [HTRN] +4.21%
MEDICALCV INC [MCVI.OB] +3.66%

Medical Instruments & Supplies

VYTERIS HOLDINGS NV [VYHN.OB] +18.10%
CANTEL MEDICAL CORP [CMN] +12.04%
QUANTRX BIOMEDICAL [QTXB.OB] +11.03%
IMPLANT SCIENCES CP [IMX] +6.67%
ROCHESTER MEDICAL [ROCM] +5.58%

Medical Laboratories & Research

SPHERIX INC [SPEX] +9.30%
GENOMIC HEALTH, INC. [GHDX] +8.92%
AASTROM BIOSCIENCE [ASTM] +5.80%
OSI PHARMACEUTIC [OSIP] +4.18%
ALLIANCE IMAGING INC [AIQ] +1.93%

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618